

Transtema Q1 Preview - Nordic exposure in favour

Redeye sees an interesting opportunity in Transtema, which is trading close to its four-year low despite momentum in its Swedish operations. At worst, Transtema has a slight indirect exposure to geopolitical turmoil, but the share has declined ~15% YTD.

Read more and download the Research Update.

Follow companies at Redeye to receive the latest equity research within Life Science and Technology.

This is a press release from Redeye - Research Powered Investment Banking. www.redeye.se/

Attachments

Transtema Q1 Preview - Nordic exposure in favour